Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy

Tumor Biology

Volumn 34, Issue 1, 2013, Pages 81-90

  Stoetzer, Oliver J ^a   Fersching, Debora M I ^b   Salat, Christoph ^a   Steinkohl, Oliver ^c   Gabka, Christian J ^c   Hamann, Ulrich ^d   Braun, Michael ^d   Feller, Axel Mario ^e   Heinemann, Volker ^b   Siegele, Barbara ^b   Nagel, Dorothea ^b   Holdenrieder, Stefan ^b,f  

^a Haematology and Oncology Outpatient Cancer Care Center   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Klinikum Dritter Orden   (Germany)

^d Red Cross Breast Cancer Center II   (Germany)

^e Breast Cancer Center Dr Geisenhofer   (Germany)

^f UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Biomarkers; Breast cancer; CA 15 3; CEA; Chemotherapy; HMGB1; Immunogenic cell death; RAGE; Serum; Therapy monitoring

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HIGH MOBILITY GROUP B1 PROTEIN; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BREAST CANCER; BREAST DISEASE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TREATMENT RESPONSE;

EID: 84872798053     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0513-1     Document Type: Article

References (52)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Ozols RF, Herbst RS, Colson YL, et al. American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol. 2007;25:146-62.
3. Bundret NJ. Prognostic and predictive factors in breast cancer. Cancer Trial Rev. 2001;27:137-42.
4. Von Minckwitz G. Neoadjuvant chemotherapy in breast cancer - insights from the German experience. Breast Cancer 2012; published online.
5. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet. 2005;365:1687-717.
6. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
7. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-85.
8. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508-16.
9. Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother. 2008;57:759-75.
10. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:e11-79.
11. Holdenrieder S, Stieber P. Apoptotic markers in cancer. Clin Biochem. 2004;37:605-17.
12. Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Lab Med Sci. 2009;46:1-24.
13. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367-88.
14. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59-73.
15. Holdenrieder S, Stieber P, von Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non small cell lung cancer. Clin Cancer Res. 2004;10:5981-7.
16. Holdenrieder S, Stieber P, von Pawel J, et al. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann N Y Acad Sci. 2006;1075:244-75.
17. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331-42.
18. Bianchi ME. HMGB1 loves company. J Leukocyte Biology. 2009;86:573-76.
19. Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008;205:3007-18.
20. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death and Differentiation. 2008;15:3-12.
21. Park JS. G-RF, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al.: High mobility group box 1 protein interacts with multiple toll-like receptors. Am J Physiol Cell Physiol. 2006;290:917-24.
22. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, Kroemer G. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009;14:364-75.
23. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050-9.
24. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68:4026-30.
25. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, Lim JB. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med. 2009;7:38.
26. Naumnik W, Nilklińska W, Ossolińska M, Chyczewska E. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol. 2009;47:703-9.
27. Tang DL, Kang R, Zeh HJ, Lotze MT. High-mobility group box 1 and cancer. Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms. 2010;1799:131-40.
28. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologica. 2009;52:2251-63.
29. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. Journal of Translational Medicine. 2010;7:17.
30. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13:1971-8.
31. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-16.
32. Lehner J, Wittwer C, Fersching D, Siegele B, Holdenrieder S, Stoetzer OJ. Methodical and preanalytical evaluation of an HMGB1 immunoassay. Anticancer Res. 2012;32:2059-62.
33. Wittwer C, Lehner J, Fersching D, Siegele B, Stoetzer OJ, Holdenrieder S. Methodical and preanalytical evaluation of a RAGE immunoassay. Anticancer Res. 2012;32:2075-78.
34. Holdenrieder S, Nagel D, Stieber P. Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer. Cancer Biomarkers. 2010;6:179-90.
35. Barak V, Holdenrieder S, Nisman B, Stieber P. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomarkers. 2010;6:191-6.
36. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11:36-44.
37. Holdenrieder S. v Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin Cancer Res. 2008;14:7813-21.
38. Kremer A, Wilkowski R, Holdenrieder S, et al. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumour Biol. 2005;26:44-9.
39. Kremer A, Holdenrieder S, Stieber P, et al. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumour Biol. 2006;27:235-42.
40. Stötzer OJ, Fersching DIM, Salat C, Siegele B, Nagel D, Holdenrieder S. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating circulating nucleosomes, DNAse activity, M30 and survivin. Cancer Lett, submitted
41. Jiao L, Weinstein SJ, Albanes D, Taylor PR, Graubard BI, Virtamo J, Stolzenberg-Solomon RZ. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res. 2011;71:3582-9.
42. Krechler T, Jáchymová M, Mestek O, Zák A, Zima T, Kalousová M. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem. 2010;43:882-6.
43. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:1430-8.
44. Jing R, Cui M, Wang J, Wang H. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma. 2010;57:55-61.
45. Tesarová P, Kalousová M, Jáchymová M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE) - soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 2007;25:720-5.
46. Shang GH, Jia CQ, Tian H, Xiao W, Li Y, Wang AH, Dong L, Lin DJ. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med. 2009;103:1949-53.
47. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W, Li YQ. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 2008;40:446-52.
48. Sheng X, Du X, Zhang X, Li D, Lu C, Li Q, Ma Z, Song Q, Wang C. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J. 2009;50:455-64.
49. Urbonaviciute V, Fürnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol. 2007;81:67-74.
50. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281-93.
51. Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, Stieber P. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res. 2007;27:1963-8.
52. Molina R, Gion M, Gressner A, Troalen F, Auge JM, Holdenrieder S, Zancan M, Wycislo M, Stieber P. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System. Clin Chem Lab Med. 2008;46:612-22.